Pfizer stock jumps after it reports positive data in early-stage coronavirus vaccine trial

spike

Pfizer shares jumped 4% Wednesday after it released positive results from its closely watched early-stage human trial of a coronavirus vaccine. 

The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo. 

The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv. The company said the levels

Read More

Moderna shares surge 30% after reporting ‘positive’ data on early-stage coronavirus vaccine trial

spike

Scientist Xinhua Yan works in the lab at Moderna in Cambridge, Massachusetts, on Feb. 28, 2020. Moderna has developed the first experimental coronavirus medicine, but an approved treatment is more than a year away.

David L. Ryan | Boston Globe | Getty Images

Moderna’s closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday, sending the company’s shares surging as much as 30% in premarket trading.

Each participant received a 25 microgram, 100 mcg or 250 mcg dose, with 15 people in each dose group. Study participants received

Read More